AcelRx Pharmaceuticals of Redwood City, California, is buying Watertown, Massachusetts-based TetraPhase Pharmaceuticals for $14.4 million.
Pharmacosmos Therapeutics Inc. was established as a newly formed specialty pharmaceutical company dedicated to commercializing Monoferric for iron deficiency anemia (IDA) patients in the United States.
Raj Kannan was appointed CEO of Chiasma Inc.
Tumble blender technology enhances the speed and homogeneous blending of tablets and capsules with trace levels of additives To meet stringent regulatory requirements, such as the United States Pharmacopeia (USP), National Formulary (NF) or FDA, as well as production and budgetary demands, pharmaceutical manufacturers require high-volume precision blending of formulations on equipment that […]
Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.
The U.S. FDA accepted for review Foamix Pharmaceuticals Ltd.’s New Drug Application (NDA) for FMX101 for treating inflammatory lesions of non-nodular moderate-to-severe acne vulgaris.
SCOUT, a leading healthcare marketing agency focused on orphan drugs and specialty pharmaceuticals, formed a joint venture with Rare Expertise, a company with proprietary data-driven tools for identifying and activating people with rare disorders.
Britain’s Consort Medical Plc agreed to develop a nasal spray for treating opioid overdoses with specialty pharmaceutical company Opiant Pharmaceuticals Inc.
Express Scripts Holding Co. built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now the pharmacy benefit manager is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.
Jacob Chacko, M.D., is now CEO of ORIC Pharmaceuticals. Rich Heyman, Ph.D., who served as the interim CEO, became chairman of the ORIC board of directors. The former chairman, Peter Svennilson, remains on the board.